Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHA:688192)

Market Cap	20.07B
Revenue (ttm)	360.39M
Net Income (ttm)	-856.77M
Shares Out	417.65M
EPS (ttm)	-2.07
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,222,945
Average Volume	2,586,422
Open	47.99
Previous Close	48.25
Day's Range	47.47 - 50.38
52-Week Range	32.72 - 51.15
Beta	0.24
RSI	68.98
Earnings Date	Apr 30, 2025

About SHA:688192

Dizal (Jiangsu) Pharmaceutical Co., Ltd. discovers, develops, and commercializes medicines in the areas of cancer and immunological diseases. It develops JAUKPO, which is in Phase II clinical trials for the treatment of hematological malignancy and immunological diseases; DZD8586 that is in Phase I for the treatment of hematological malignancy; ZEGFROVY, which is in Phase II clinical trials for the treatment of solid tumors; DZD1516 that is in Phase II clinical trials for the treatment of solid tumors; and DZD2269, which is in Phase I clinical ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2017
• Employees: 581
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688192

Financial Performance

In 2024, SHA:688192's revenue was 360.39 million, an increase of 294.79% compared to the previous year's 91.29 million. Losses were -856.77 million, -22.65% less than in 2023.